Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31415Editorial articleПередовая статьяReview ArticleHypoglycemia in patients with type 2 diabetes mellitus: Safe solution of the dangerous problemГипогликемия у пациентов с сахарным диабетом 2-го типа: безопасное решение опасной проблемыShestakovaM VШестаковаМ Вnephro@endocrincentr.ruKhalimovIu ShХалимовЮ Шyushkha@gmail.comЭндокринологический научный центр Минздрава РоссииМГМУ им. И.М. Сеченова, МоскваВоенно-медицинская академия им. С.М. Кирова, Санкт-Петербург151220138512VOL 85, NO12 (2013)ТОМ 85, №12 (2013)14415010042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31415

The review gives detailed information on the state-of-the-art of hypoglycemia (HG) and the results of its Russian and international trials. It is noted that HG should be now regarded as an extremely undesirable glucose-lowering therapy complication that is closely related to the risk of cardiovascular events and higher mortality rates, worse glycemic control, and poorer quality of life in patients with type 2 diabetes mellitus (T2DM). The priority effective therapy tactics for T2DM is to manage the latter without any risk of HG, which can be implemented by the wide clinical application of incretins, dipeptidyl peptidase-4 inhibitors in particular, which have the glucose-lowering activity comparable with that shown by metformin and sulfonylurea drugs, are practically safe when used as monotherapy and significantly enhance the efficiency of therapy without substantially increasing the risk of severe HG when co-administered with other medications.

Аннотация.В обзоре приводятся подробные сведения о состоянии проблемы и результатах современных национальных и международ­ных исследований. Отмечено, что гипогликемию (ГГ) в настоящее время следует рассматривать как крайне нежелательное осложнение сахароснижающей терапии, которое у больных сахарным диабетом 2-го типа (СД-2) тесно ассоциировано с риском развития сердечно-сосудистых осложнений и повышенной летальностью, ухудшением гликемического контроля и снижением качества жизни. Приоритетной тактикой эффективной терапии СД-2 является управление СД без риска развития ГГ, реализовать которую позволит широкое применение в клинической практике инкретиновых препаратов, в частности ингибиторов дипептидилпептидазы 4-го типа, которые обладают сахароснижающей активностью, сравнимой с таковой метформина и препаратов сульфонилмочевины, практически безопасны при использовании в качестве монотерапии, а при комбинации с другими препаратами достоверно увеличивают эффективность лечения без значимого повышения риска развития тяжелых ГГ.

type 2 diabetes mellitushypoglycemiaglucose-lowering therapydipeptidyl peptidase-4 inhibitorsсахарный диабет 2-го типагипогликемиясахароснижающая терапияингибиторы дипептидилпептидазы 4-го типаFrier B.M., Schernthaner G., Heller S.R. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34 (Suppl 2): S132-137.Bonds D.E., Miller M.E., Bergenstal R.M. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: 4909.Cryer P.E. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35: 1814-1816.Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.Seaquist E.R., Anderson J., Childs B. et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes care 2013; 36 (5): 1384-1395.Adler G.K., Bonyhay I., Failing H. et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009; 58 (2): 360-366.Дедов И.И., Шестакова М.В., Александров А.А. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. М 2013; 120.Zoungas S., Patel A., Chalmers J. et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.Cryer P.E. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011; 124: 993-996.Choudhary P., Amiel S.A. Hypoglycaemia: current management and controversies. Postgrad Med J 2011; 87 (1026): 298-306.McCoy R.G., Van Houten H.K., Ziegenfuss J.Y. et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35 (9): 1897-1901.Tanenberg R.J., Newton C.A., Drake A.J. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system Endocr Pract 2010; 16: 244-248.Lalic N.M. The Case for: Hypoglycemia Is of Cardiovascular Importance. Diabetes Care 2013; 36 (Suppl 2): S264-266.O'Keefe J.H., Abuannadi M., Lavie C.J., Bell D.S. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011; 86 (2): 128-138.Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (6): 1364-1379.Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2-го типа. Сахарный диабет 2011; 4: 6-17.Campbell P.T., Newton C.C., Patel A.V. et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35 (9): 1835-1844.Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabet Obes Metabol 2008; 10 (11) : 1128-1129.Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394.Roumie C.L., Hung A.M., Greevy R.A. et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157 (9): 601-610.Donath M.Y., Burcelin R. GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine? Diabetes Care 2013; 36 (Suppl 2): S145-S148.Cahn A., Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013; 18 (2): 245-258.Seck T., Nauck M., Sheng D. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. J Clin Pract 2010; 64 (5): 562-576.Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13 (2): 160-168.Rathmann W., Kostev K., Gruenberger J.B. et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013; 15 (1): 55-61.Kirkman M.S., Briscoe V.J., Clark N. et al. Diabetes in older adults. Diabetes Care 2012; 35 (12): 2650-2664.Fu A.Z., Qiu Y., Davies M.J., Engel S.S. Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther 2012; 3 (1): 12.Barzilai N., Guo H., Mahoney E.M. et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Bar Curr Med Res Opin 2011; 27 (5): 1049-1058.Penfornis A., Bourdel-Marchasson I., Quere S., Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab 2012; 38 (6): 550-557.Hage C., Brismar K., Efendic S. et al. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities - the BEGAMI study. J Intern Med 2013; 273 (4): 410-421.Scheen A.J. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: From risk factors to clinical outcomes. Postgrad Med 2013; 125 (3): 7-20.Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36 (Suppl 2): S139-144.Garber A.J., Abrahamson M.J., Barzilay J.I. et al. AACE Comprehensive Diabetes Management Algorithm 2013. J Endocr Pract 2013; 19 (2): 327-336.